• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.

    5/12/25 10:44:45 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $APGE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Apogee Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    03770N101

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03770N101


    1Names of Reporting Persons

    Wellington Management Group LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,106,377.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,485,754.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,485,754.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    03770N101


    1Names of Reporting Persons

    Wellington Group Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,106,377.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,485,754.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,485,754.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    03770N101


    1Names of Reporting Persons

    Wellington Investment Advisors Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,106,377.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,485,754.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,485,754.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    03770N101


    1Names of Reporting Persons

    Wellington Management Company LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,101,954.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,334,852.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,485,754.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.6 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Apogee Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    221 Crescent St, Building 17, Suite 102B, Waltham MA 02453
    Item 2. 
    (a)Name of person filing:

    Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP
    (b)Address or principal business office or, if none, residence:

    c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
    (c)Citizenship:

    Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    03770N101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the responses to Item 9 on the attached cover pages.
    (b)Percent of class:

    11.92  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    See the responses to Item 8 on the attached cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Vanguard Health Care Fund
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Wellington Management Group LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:05/12/2025
     
    Wellington Group Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:05/12/2025
     
    Wellington Investment Advisors Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:05/12/2025
     
    Wellington Management Company LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:05/12/2025
    Get the next $APGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APGE

    DatePrice TargetRatingAnalyst
    3/13/2025$95.00Buy
    Citigroup
    11/25/2024$89.00Buy
    Canaccord Genuity
    5/10/2024$80.00Buy
    BofA Securities
    12/20/2023$43.00Buy
    BTIG Research
    8/8/2023Outperform
    TD Cowen
    8/8/2023$40.00Outperform
    Wedbush
    8/8/2023$29.00Buy
    Guggenheim
    8/8/2023$34.00Buy
    Stifel
    More analyst ratings

    $APGE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

      Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026 APG279 on track to initiate Phase 1b head-to-head trial vs DUPIXENT in 2025 with readout expected in 2H 2026 Positive interim Phase 1b readout of APG808 in patients with mild-to-moderate asthma demonstrated rapid, robust and sustained suppression of FeNO, a biomarker of Type 2 inflammation that is associated with exacerbations in asthma $681.4 million cash, cash equivalents and marketable securities supports runway into Q1 2028

      5/12/25 6:05:00 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

      Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53% APG808 demonstrated the potential for durable disease control in asthma with sustained FeNO decrease from baseline of 50% at 12 weeks APG808's optimized formulation and potential best-in-class pharmacokinetic (PK) profile, combined with robust and sustained FeNO suppression through 12 weeks, support the potential for transformative dosing every 2-months or longer, compared to the current biweekly standard of care APG808 was well tolerated with a favorable safety profile consistent with the anti-

      5/12/25 6:00:00 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

      SAN FRANCISCO and BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will present at the Bank of America Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T. / 4:40 p.m. E.T. A live and archived webcast of the presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, COPD and other I&I indications. Apogee's anti

      5/1/25 8:00:00 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Dambkowski Carl sold $97,419 worth of shares (2,725 units at $35.75), decreasing direct ownership by 1% to 244,448 units (SEC Form 4)

      4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

      5/9/25 8:01:12 PM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Dambkowski Carl sold $139,801 worth of shares (3,860 units at $36.22), decreasing direct ownership by 2% to 247,173 units (SEC Form 4)

      4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

      4/4/25 8:01:18 PM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Dambkowski Carl sold $48,463 worth of shares (1,590 units at $30.48), decreasing direct ownership by 0.63% to 251,033 units (SEC Form 4)

      4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

      3/7/25 8:02:04 PM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Apogee Therapeutics with a new price target

      Citigroup initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $95.00

      3/13/25 7:25:29 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Canaccord Genuity initiated coverage on Apogee Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $89.00

      11/25/24 7:29:35 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities initiated coverage on Apogee Therapeutics with a new price target

      BofA Securities initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $80.00

      5/10/24 7:29:58 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

      SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

      11/14/24 5:46:11 PM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Apogee Therapeutics Inc.

      SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)

      11/14/24 11:16:12 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

      SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

      11/14/24 10:18:32 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APGE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mckenna Mark C. bought $990,775 worth of shares (20,000 units at $49.54) (SEC Form 4)

      4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

      12/16/24 6:00:10 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APGE
    Leadership Updates

    Live Leadership Updates

    See more
    • Apogee Therapeutics Announces Agenda for Virtual R&D Day

      SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t

      11/29/24 1:00:00 PM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

      SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of

      11/18/24 7:30:00 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

      SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy,

      9/9/24 7:00:00 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APGE
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.

      SCHEDULE 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

      5/12/25 10:44:45 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Apogee Therapeutics Inc.

      10-Q - Apogee Therapeutics, Inc. (0001974640) (Filer)

      5/12/25 6:30:23 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Apogee Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)

      5/12/25 6:15:27 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APGE
    Financials

    Live finance-specific insights

    See more
    • Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

      SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report interim results from the Phase 1 APG990 healthy volunteer trial on Monday, March 3, 2025. Following the announcement, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for i

      2/28/25 4:00:00 PM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days

      Pharmacokinetic data support potential best-in-class profile with potential for improved clinical responses from greater exposures in induction than currently available biologic therapies and maintenance dosing of every 3- or 6-months Single dose showed deep and sustained inhibition of key atopic dermatitis biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available with inhibition still ongoing at time of data cut) APG777 was well tolerated with a favorable safety profile consistent with the anti-IL-13 class Company plans to initiate a randomized, placebo-controlled, 16-week Phase 2 clinical trial in patients with moderate-to-severe atopic dermatitis in 1H 2024 with induction r

      3/5/24 6:00:00 AM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

      SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced it will report interim results from the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5, 2024. Following the announcement, the Company will host a conference call and webcast at 7:00am ET to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Apogee's website at https://investors.apogeeth

      3/4/24 4:01:00 PM ET
      $APGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care